CA2838289C - Sustained release formulations for delivery of proteins to the eye and methods of preparing same - Google Patents

Sustained release formulations for delivery of proteins to the eye and methods of preparing same Download PDF

Info

Publication number
CA2838289C
CA2838289C CA2838289A CA2838289A CA2838289C CA 2838289 C CA2838289 C CA 2838289C CA 2838289 A CA2838289 A CA 2838289A CA 2838289 A CA2838289 A CA 2838289A CA 2838289 C CA2838289 C CA 2838289C
Authority
CA
Canada
Prior art keywords
formulation
liquid
plga
inhibits
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2838289A
Other languages
English (en)
French (fr)
Other versions
CA2838289A1 (en
Inventor
Vernon G. Wong
Louis L. Wood
Glenn T. Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramscor Inc
Icon Bioscience Inc
Original Assignee
Ramscor Inc
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc, Icon Bioscience Inc filed Critical Ramscor Inc
Publication of CA2838289A1 publication Critical patent/CA2838289A1/en
Application granted granted Critical
Publication of CA2838289C publication Critical patent/CA2838289C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2838289A 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same Active CA2838289C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (2)

Publication Number Publication Date
CA2838289A1 CA2838289A1 (en) 2013-03-14
CA2838289C true CA2838289C (en) 2019-09-10

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838289A Active CA2838289C (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Country Status (22)

Country Link
US (1) US9814773B2 (enExample)
EP (1) EP2717914B1 (enExample)
JP (1) JP6339011B2 (enExample)
KR (1) KR20140060274A (enExample)
CN (1) CN103945865B (enExample)
AU (1) AU2012304909B2 (enExample)
BR (1) BR112013031685B1 (enExample)
CA (1) CA2838289C (enExample)
CY (1) CY1122771T1 (enExample)
DK (1) DK2717914T3 (enExample)
ES (1) ES2761340T3 (enExample)
HR (1) HRP20192276T1 (enExample)
HU (1) HUE047737T2 (enExample)
IN (1) IN2013MN02384A (enExample)
LT (1) LT2717914T (enExample)
MX (1) MX359119B (enExample)
PL (1) PL2717914T3 (enExample)
PT (1) PT2717914T (enExample)
RS (1) RS60051B1 (enExample)
SI (1) SI2717914T1 (enExample)
SM (1) SMT202000021T1 (enExample)
WO (1) WO2013036309A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913336C (en) * 2013-05-24 2020-12-15 Icon Bioscience, Inc. Use of sustained release dexamethasone in post-cataract surgery inflammation
JP6629840B2 (ja) * 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
HK1246641A1 (zh) * 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
US10786515B2 (en) * 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
EP3749386B1 (en) 2018-02-09 2026-04-15 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
EP4652999A3 (en) 2018-05-01 2026-02-18 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2019213326A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
ES2672806T3 (es) * 2009-07-03 2018-06-18 Armbruster Biotechnology Gmbh Injerto óseo y material biocompuesto

Also Published As

Publication number Publication date
PL2717914T3 (pl) 2020-05-18
EP2717914B1 (en) 2019-10-30
NZ619707A (en) 2015-01-30
HRP20192276T1 (hr) 2020-05-15
RS60051B1 (sr) 2020-04-30
SMT202000021T1 (it) 2020-03-13
WO2013036309A3 (en) 2013-05-10
CA2838289A1 (en) 2013-03-14
CN103945865B (zh) 2016-10-26
WO2013036309A2 (en) 2013-03-14
MX2013014461A (es) 2014-05-14
US20140140992A1 (en) 2014-05-22
IN2013MN02384A (enExample) 2015-06-12
SI2717914T1 (sl) 2020-07-31
BR112013031685A2 (pt) 2017-02-07
JP6339011B2 (ja) 2018-06-06
PT2717914T (pt) 2019-12-18
DK2717914T3 (da) 2020-01-20
AU2012304909B2 (en) 2017-06-08
LT2717914T (lt) 2020-03-25
JP2014516087A (ja) 2014-07-07
KR20140060274A (ko) 2014-05-19
CY1122771T1 (el) 2021-05-05
EP2717914A2 (en) 2014-04-16
US9814773B2 (en) 2017-11-14
HUE047737T2 (hu) 2020-05-28
CN103945865A (zh) 2014-07-23
AU2012304909A1 (en) 2013-12-19
MX359119B (es) 2018-09-14
EP2717914A4 (en) 2015-05-13
ES2761340T3 (es) 2020-05-19
BR112013031685B1 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
AU2012304909B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CN101060831B (zh) 可方便植入的缓释药物组合物
Tan et al. Controlled-release nanotherapeutics: State of translation
EP2086503B1 (en) Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
Mohtashami et al. Pharmaceutical implants: Classification, limitations and therapeutic applications
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
JP6247272B2 (ja) 眼症状を処置するための高粘度高分子組成物
US20150037429A1 (en) Controlled Release Microparticles
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
EP3621588B1 (en) Ocular compositions
CA2957548A1 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP3976106A1 (en) Bioerodible polyester polymer implants and related methods of use
Ham et al. Novel drug delivery methods and approaches for the treatment of retinal diseases
Booth et al. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CA3124280A1 (en) Ocular compositions
HK1196081A (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HK1196081B (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
JP2025525881A (ja) 眼内使用するためのニンテダニブの医薬製剤
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
WO2024206077A2 (en) Dosing regimes and combination therapies using archexin for the treatment of cancer
WO2025075991A1 (en) Cai-loaded bioerodible implant and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150603

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606